Home / Investor Relations



  • Steve Hoffman

    Co-Founder, Chief Executive, and Chief Science Officer
    Steve co-founded Tyme Inc. in 2008 as the Chief Executive Officer. With more than 30 years experience in biochemistry and physics, Steve has been the lead author on over 40 patents. For the last decade, he has focused on biopharmaceuticals for oncology, metabolic syndrome, and central nervous system disorders. Prior to working in biotech, he was involved in chemistry, aerospace and laser optics. In addition to leading the scientific development for his own companies, he has worked with multiple Fortune 500 healthcare companies, academic institutions, and the US government.
    • Michael Demurjian

      Co-Founder and Chief Operating Officer
      Michael co-founded Tyme Inc. in 2008 as the Chief Operating Officer. Michael has over 25 years of executive experience with a focus on financing, operations, and marketing. He has been responsible for the overseeing the corporate and product development activities at Tyme. Prior to Tyme, Michael led the operations for Mikronite Technologies, which developed and marketed products using advanced materials science. At Mikronite, he oversaw the successful development and marketing of several products as well as implementation of collaborations with DePuy, GE and the Department of Defense.
      • Ben Taylor

        President, Chief Financial Officer
        Mr. Taylor has been Tyme’s President and Chief Financial Officer since April of 2017. He joined Tyme Inc. with 18 years of life sciences experience in investment banking and emerging growth companies. Most recently, he was Head of Commercial Pharma for Barclays Capital Inc. Prior to Barclays, Mr. Taylor spent ten years at Goldman, Sachs & Co., where he held a variety of roles, including Head of Emerging Pharma and Co-Head of Chinese and Southeast Asian Healthcare within the investment banking division. His career has primarily been focused on biopharmaceuticals, working as an advisor to over a hundred companies at various stages of development in more than 15 countries. Mr. Taylor has extensive experience in pharmaceutical business models, science, financing and strategic transactions. In addition to investment banking, he also spent two years at a medical diagnostic start-up leading finance and business development functions. Mr. Taylor graduated from Brown University with honors.
        • Dr. Giuseppe

          Chief Medical Officer

          Dr. Del Priore joined Tyme Inc. after serving as the National Director of Gynecologic Oncology for Cancer Treatment Centers of America (CTCA). He also serves as the Southeastern Regional Director. Prior to CTCA, Dr. Del Priore was Professor and Director of Gynecologic Oncology at the Indiana University School of Medicine in Indianapolis, where he directed its gynecologic oncology fellowship program and continues to teach. He previously also served as Director of Gynecologic Oncology at New York Downtown Hospital, Montefiore Medical Center, and Bellevue Hospital in New York City, as well as Assistant Director of Gynecologic Oncology at New York University School of Medicine. Giuseppe Del Priore, MD, MPH has been involved with drug, device and procedure development his entire career. He has participated and been on the advisory boards of studies for most major pharmaceutical companies. An industry KOL, his opinions have earned him invitations to present at the FDA and other regulatory agencies. His work has been reported on the front pages of the NY Times, WSJ and nearly every media outlet. He has been the principle investigator on several world firsts including breakthroughs in oncology, fertility and other areas of science. Dr. Del Priore remains a sought after clinician bringing relevant insights from actual patient challenges directly to the board room. Dr. Del Priore earned his Doctor of Medicine with Distinction in Research from State University of New York Downstate Medical Center in Brooklyn. He studied at The City University of New York’s Brooklyn College in a combined Bachelor of Arts/Doctor of Medicine Program, earning both degrees in seven years. Dr. Del Priore graduated magna cum laude with a Bachelor of Arts in Philosophy and was valedictorian of his medical school class. He received his Master of Public Health in Biostatistics and Epidemiology from the University of Illinois at Chicago and completed other training at Northwestern University and the University of Rochester. U.S. News and World Report named Dr. Del Priore one of its “Best Doctors” in 2011 and 2012.

          He is an active researcher and prolific writer. He has authored and published more than 170 papers, book chapters, and abstracts and written three books. Dr. Del Priore has received two patents and has others pending. He has served on several committees and organizations, including current appointments at the Society of Gynecologic Oncologists; and previously the Gynecologic Oncology Group, a National Cancer Institute Cooperative Group. He is also an examiner for the American Osteopathic Association Board of Obstetrics and Gynecology, Gyn Oncology subspecialty section. In his free time, Dr. Del Priore has given back to his community by serving as a volunteer physicians part of the National Association of Free and Charitable Clinics; a volunteer firefighter in Westchester County, New York; an auxiliary police officer with the New York Police Department; and a volunteer ambulance driver with the Bay Ridge Ambulance Volunteer Organization.

          • Shabnam Stanicky

            Clinical Operations Officer
            Mrs. Stanicky joined the Tyme Inc. team in January 2017 as Clinical Operations Officer. She will be focused on overseeing the operational delivery of the current and upcoming clinical trials conducted by Tyme. With over 16 years experience in clinical oncology research operations, Mrs. Stanicky has extensive experience in the management, design, execution, and evaluation of clinical trials for cancer therapies. She joins Tyme from Quintiles, where she has worked since 2008 as a Clinical Operations Manager within the Oncology therapeutic area, with specific expertise within Phase I trials. She has managed both field-based operational delivery as well as project based operations in her prior roles. Prior to that, Mrs. Stanicky worked for seven years performing and managing clinical oncology research at Eli Lilly and Co. and two years at the John Wayne Cancer Institute in Santa Monica, California.
            • Jonathan Eckard, Ph.D.

              Chief Scientific Affairs Officer

              Jonathan Eckard, Ph.D. is the new Chief Scientific Affairs Officer at Tyme Inc. Dr. Eckard has worked in the biotechnology sector and has over 10 years of financial experience following the biotechnology sector, bringing to Tyme both important industry insights and an understanding of the healthcare equity markets. During his time on Wall Street, he received several accolades including Institutional Investor “Best up-and-comer” and “Rising Star” in biotechnology research.

              Most recently Dr. Eckard was Chief Business and Strategy Officer of a oncology -focused biotechnology company. His previous finance role was as a director and senior equity research analyst at Barclays Capital Markets covering the small- and mid-cap biotechnology sector. Prior to joining Barclays, Dr. Eckard worked for three years at Citi where he was an analyst covered the biotechnology and specialty pharmaceuticals sectors. Previously he spent five years at Leerink Swann and two years at HSBC working in biotechnology equity research.

              Prior to his career in financial services, Dr. Eckard was in academia conducting cancer research and teaching at the NYU School of Medicine. He earned a BS in Biochemistry from Ohio University, an MS in Toxicology and a PhD in Toxicology and Carcinogenesis from NYU School of Medicine.